PharmaCyte Biotech, Inc. financial data

Symbol
PMCB on Nasdaq
Location
Las Vegas, NV
Fiscal year end
30 April
Latest financial report
10-Q - Q3 2025 - 18 Dec 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1207% % 98%
Debt-to-equity 16% % -66%
Return On Equity -17% % -127%
Return On Assets -14% % -140%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10,134,160 shares 45%
Common Stock, Shares, Outstanding 6,795,779 shares -12%
Entity Public Float $12,527,115 USD -31%
Common Stock, Value, Issued $2,167 USD 0%
Weighted Average Number of Shares Outstanding, Basic 6,795,779 shares -11%
Weighted Average Number of Shares Outstanding, Diluted 6,795,779 shares -11%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Research and Development Expense $481,172 USD 16%
General and Administrative Expense $3,746,099 USD -44%
Operating Income (Loss) $4,227,271 USD 43%
Nonoperating Income (Expense) $2,846,545 USD -109%
Net Income (Loss) Attributable to Parent $7,073,816 USD -131%
Earnings Per Share, Basic -0.79 USD/shares -255%
Earnings Per Share, Diluted -0.79 USD/shares -255%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $15,406,017 USD -26%
Marketable Securities, Current $201,190 USD
Assets, Current $23,022,354 USD 7.9%
Intangible Assets, Net (Excluding Goodwill) $1,549,427 USD 0%
Assets $55,976,469 USD 1.6%
Accounts Payable, Current $1,021,339 USD 193%
Accrued Liabilities, Current $520,656 USD -26%
Liabilities, Current $1,577,384 USD -67%
Liabilities $19,422,384 USD 67%
Accumulated Other Comprehensive Income (Loss), Net of Tax $24,127 USD -3.7%
Retained Earnings (Accumulated Deficit) $100,747,031 USD -7.6%
Stockholders' Equity Attributable to Parent $35,235,089 USD -19%
Liabilities and Equity $55,976,469 USD 1.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,993,981 USD -434%
Net Cash Provided by (Used in) Financing Activities $0 USD
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 21,672,095 shares 0%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,993,858 USD 89%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $15,406,017 USD -26%
Deferred Tax Assets, Valuation Allowance $15,221,718 USD 0.18%
Deferred Tax Assets, Gross $16,914,188 USD 4.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $7,074,676 USD -131%
Deferred Tax Assets, Operating Loss Carryforwards $15,026,112 USD 4.1%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $180,611,996 USD -0.41%
Deferred Tax Assets, Net of Valuation Allowance $15,221,718 USD 0.18%